Identification of new selective CD36 inhibitors to potentiate HER2-targeted therapy in HER2-positive breast cancer.

ABSTRACT: HER2 overexpression/amplification (HER2+) occurs in approximately 15-20% of breast cancer (BC) and identifies a highly aggressive BC subtype. The cure rate of HER2 + BC has been significantly increased through recent clinical achievements; however, a non-negligible proportion of patients still either fails to respond or acquires resistance to targeted therapies, highlighting the need for novel treatment strategies. As demonstrated in robust preclinical studies, HER2 + BC is considered a neoplastic disease with a peculiar lipogenic phenotype, due to its crucial addiction to an exacerbated need for fatty acids (FAs) produced via FA synthase (FASN), the central lipogenic enzyme required for intracellular de novo FA biosynthesis. FASN is overexpressed/activated in most HER2 + BC cells sustaini

SUBMITTER: Castagnoli L 

PROVIDER: S-EPMC12328627 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature